Positive Lynparza readout

AstraZeneca has just announced positive Breast cancer results from a head to head Phase III trial which compares its PARP inhibitor, called Lynparza versus physician’s choice chemotherapy in 1st- to 3rd-line germline BRCA mutation positive metastatic breast cancer patients.
Results showed a statistically significant and clinically meaningful improvement in progression free survival compared with those who received chemotherapy.

These results are positive news for patients with BRCA-mutated metastatic breast cancer, a disease with a high unmet need, and are the first positive Phase III data for a PARP inhibitor beyond ovarian cancer. This is highly encouraging for the development of our broad portfolio which aims to treat multiple cancers by targeting DNA damage response pathways.

After a disappointing readout of Abbvie’s Phase II BROCADE trial of their PARP, AstraZeneca could now be the first company to make available its PARP inhibitor to breast cancer patients.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s